An evaluation of fulvestrant for the treatment of metastatic breast cancer

References

• Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.
   PubMed Web of Science ®Google Scholar
• Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233–247.
   PubMed Web of Science ®Google Scholar
• Gottardis MM, Jordan VC. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 1988;48(18):5183–5187.
   PubMed Web of Science ®Google Scholar
• Gottardis MM, Wagner RJ, Borden EC, et al. Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in Vivo and in Vitro. Cancer Res. 1989;49(17):4765–4769.
   PubMed Web of Science ®Google Scholar
• Gottardis MM, Jiang S-Y, Jeng M-H, et al. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res. 1989;49(15):4090–4093.
   PubMed Web of Science ®Google Scholar
• Gottardis MM, Ricchio ME, Satyaswaroop PG, et al. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Res. 1990 Jun 1;50(11):3189–3192.
   PubMed Web of Science ®Google Scholar
• Bowler J, Lilley TJ, Pittam JD, et al. Novel steroidal pure antiestrogens. Steroids. 1989;54(1):71–99.
   PubMedGoogle Scholar
• Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51(15):3867–3873.
   PubMed Web of Science ®Google Scholar
• Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci. 1993 Dec;106(Pt 4):1377–1388.
   PubMed Web of Science ®Google Scholar
• Osborne CK, Wakeling A, Nicholson RI. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004;90(Suppl 1):S2–S6.
   PubMed Web of Science ®Google Scholar
• Howell A, Osborne CK, Morris C, et al. ICI 182,780 (Faslodex): development of a novel, “pure” antiestrogen. Cancer. 2000 Aug 15;89(4):817–825.
   PubMed Web of Science ®Google Scholar
• Tzukerman MT, Esty A, Santiso-Mere D, et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol. 1994;8(1):21–30.
   PubMedGoogle Scholar
• Nicholson RI, Gee JM, Manning DL, et al. Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer. Ann N Y Acad Sci. 1995 Jun 12;761:148–163.
   PubMed Web of Science ®Google Scholar
• Harrison M, Laight A, Clarke D, et al., editors. Pharmacokinetics and metabolism of fulvestrant after oral, intravenous and intramuscular administration in healthy volunteers. Proc ASCO. 2003;21:45.
   Google Scholar
• Robertson JF, Harrison MP. Equivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant (‘Faslodex’) in postmenopausal women with advanced breast cancer. Cancer Chemother Pharmacol. 2003 Oct;52(4):346–348.
   PubMed Web of Science ®Google Scholar
• Robertson J, Harrison M, editors. ICI 182,780 (‘Faslodex’)(FAS) 250 mg monthly intramuscular (im) injection shows consistent PK during long-term dosing in postmenopausal (PM) women with advanced breast cancer (ABC). Proc Am Assoc Cancer Res. 2001;42:856.
   Google Scholar
• DeFriend DJ, Howell A, Nicholson RI, et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res. 1994 Jan 15;54(2):408–414.
   PubMed Web of Science ®Google Scholar
• Robertson JF, Erikstein B, Osborne KC, et al. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer. Clin Pharmacokinet. 2004;43(8):529–538.
   PubMed Web of Science ®Google Scholar
• McCormack P, Sapunar F. Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor–positive advanced breast cancer. Clin Breast Cancer. 2008 Aug 01;8(4):347–351.
   PubMed Web of Science ®Google Scholar
• Ohno S, Kamigaki S, Noguchi S, et al. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). Ann Oncol. 2010;21(12):2342–2347.
   PubMed Web of Science ®Google Scholar
• Robertson JFR, Harrison M. Fulvestrant: pharmacokinetics and pharmacology. Br J Cancer. 2004;90(Suppl 1):S7–S10.
   PubMed Web of Science ®Google Scholar
• Laight A, Yates R, Rose A, et al., editors.. Fulvestrant is unlikely to be involved in clinically significant drug interactions–results of clinical trials in healthy male volunteers. Proc ASCO. 2003;22:33.
   Google Scholar
• Howell A, Robertson JF, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002 Aug 15;20(16):3396–3403.
   PubMed Web of Science ®Google Scholar
• Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002 Aug 15;20(16):3386–3395.
   PubMed Web of Science ®Google Scholar
• Howell A, Pippen J, Elledge RM, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer. 2005 Jul 15;104(2):236–239.
   PubMed Web of Science ®Google Scholar
• Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004 May 1;22(9):1605–1613.
   PubMed Web of Science ®Google Scholar
• Pritchard KI, Rolski J, Papai Z, et al. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer Res Treat. 2010 Sep;123(2):453–461.
   PubMed Web of Science ®Google Scholar
• Ohno S, Rai Y, Iwata H, et al. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). Ann Oncol. 2010 Dec;21(12):2342–2347.
   PubMed Web of Science ®Google Scholar
• Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010 Oct 20;28(30):4594–4600.
   PubMed Web of Science ®Google Scholar
• Di Leo A, Jerusalem G, Petruzelka L, et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst. 2014 Jan;106(1):djt337.
   PubMedGoogle Scholar
• Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol. 2009 Sep 20;27(27):4530–4535.
   PubMed Web of Science ®Google Scholar
• Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016 Dec 17;388(10063):2997–3005.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017 Nov 10;35(32):3638–3646.
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–1748.
   PubMed Web of Science ®Google Scholar
• George W, Sledge J, Toi M, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–2884.
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016 Apr;17(4):425–439.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465–2472.
   PubMed Web of Science ®Google Scholar
• Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926–1936.
   PubMed Web of Science ®Google Scholar
• Goss P, Bondarenko IN, Manikhas GN, et al. Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer. J Clin Oncol. 2007 Nov 01;25(31):4961–4966.
   PubMed Web of Science ®Google Scholar
• Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002 Jun 22;359(9324):2131–2139.
   PubMed Web of Science ®Google Scholar
• Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. JNCI. 1995;87(10):746–750.
   PubMed Web of Science ®Google Scholar
• Macedo LF, Sabnis GJ, Goloubeva OG, et al. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model. Cancer Res. 2008 May 1;68(9):3516–3522.
   PubMed Web of Science ®Google Scholar
• Bergh J, Jönsson P-E, Lidbrink EK, et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol. 2012 Jun 01;30(16):1919–1925.
   PubMed Web of Science ®Google Scholar
• Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med. 2012 Aug 2;367(5):435–444.
   PubMed Web of Science ®Google Scholar
• Mehta RS, Barlow WE, Albain KS, et al. Overall survival with fulvestrant plus anastrozole in metastatic breast cancer. N Engl J Med. 2019;380(13):1226–1234.
   PubMed Web of Science ®Google Scholar
• Johnston SR, Kilburn LS, Ellis P, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol. 2013 Sep;14(10):989–998.
   PubMed Web of Science ®Google Scholar
• Gutierrez MC, Detre S, Johnston S, et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 2005;23(11):2469–2476.
   PubMed Web of Science ®Google Scholar
• Drury SC, Detre S, Leary A, et al. Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocr Relat Cancer. 2011 Oct;18(5):565–577.
   PubMed Web of Science ®Google Scholar
• Kaminska KK, Akrap N, Staaf J, et al. Abstract 5907: Fulvestrant resistance in estrogen receptor positive breast cancer models is driven by heterogeneous ER independent transcriptional programs. Cancer Research. 2018;78(13 Supplement):5907–5907.
   Google Scholar
• Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013 Dec;45(12):1439–1445.
   PubMed Web of Science ®Google Scholar
• Jeselsohn R, Yelensky R, Buchwalter G, et al. Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res off J Am Assoc Cancer Res. 2014 Apr 1;20(7):1757–1767.
   PubMed Web of Science ®Google Scholar
• Fribbens C, O’Leary B, Kilburn L, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2016 Sep 1;34(25):2961–2968.
   PubMed Web of Science ®Google Scholar
• Mendoza MC, Blenis J Er EE. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;36(6):320–328.
   PubMed Web of Science ®Google Scholar
• Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008;68(15):6084–6091.
   PubMed Web of Science ®Google Scholar
• Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell. 2010;40(2):310–322.
   PubMed Web of Science ®Google Scholar
• Gingras A-C, Kennedy SG, O’Leary MA, et al. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt (PKB) signaling pathway. Genes Dev. 1998;12(4):502–513.
   PubMed Web of Science ®Google Scholar
• Beeram M, Tan Q-T, Tekmal R, et al. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol. 2007;18(8):1323–1328.
   PubMed Web of Science ®Google Scholar
• Lundgren K, Brown M, Pineda S, et al. Effects of cyclin D 1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Breast Cancer Res. 2012;14(2):R57.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Moerkens M, Ramaiahgari S, et al. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res. 2011;13(3):R52.
   PubMed Web of Science ®Google Scholar
• Arpino G, Wiechmann L, Osborne CK, et al. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008;29(2):217–233.
   PubMed Web of Science ®Google Scholar
• Lonning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol. 2000 Jun;18(11):2234–2244.
   PubMed Web of Science ®Google Scholar
• Lenihan C, Bouchekioua-Bouzaghou K, Abdulghani R, et al. Abstract P3-03-12: CDK4/6 inhibitor resistant ER-positive cells remain dependent on estrogen signalling and retain sensitivity to endocrine therapy. Cancer Res. 2017;77(4 Supplement):P3-03–12-P3-03–12.
   Google Scholar
• Kornblum N, Zhao F, Manola J, et al. Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102. J Clin Oncol. 2018 Jun 01;36(16):1556–1563.
   PubMed Web of Science ®Google Scholar
• Baselga J, Im SA, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Jul;18(7):904–916.
   PubMed Web of Science ®Google Scholar
• Campone M, Im SA, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. Eur j cancer. 2018;103:147–154.
   PubMed Web of Science ®Google Scholar
• Di Leo A, Johnston S, Lee KS, et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 Jan;19(1):87–100.
   PubMed Web of Science ®Google Scholar
• Krop IE, Mayer IA, Ganju V, et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17(6):811–821.
   PubMed Web of Science ®Google Scholar
• Ndubaku CO, Heffron TP, Staben ST, et al. Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a beta-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity. J Med Chem. 2013 Jun 13;56(11):4597–4610.
   PubMed Web of Science ®Google Scholar
• Dickler MN, Saura C, Richards DA, et al. Phase II study of taselisib (GDC-0032) in combination with fulvestrant in patients with HER2-negative, hormone receptor–positive advanced breast cancer. Clin Cancer Res. 2018;24(18):4380.
   PubMed Web of Science ®Google Scholar
• Juric D, Janku F, Rodón J, et al. Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor–positive advanced breast cancer: a phase 1b clinical trialalpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor–positive breast canceralpelisib plus fulvestrant in PIK3CA-Altered and PIK3CA-wild-type estrogen receptor–positive breast cancer. JAMA Oncol. 2019;5(2):e184475–e184475.
   PubMed Web of Science ®Google Scholar
• André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–1940.
   PubMed Web of Science ®Google Scholar
• Turner N, Pearson A, Sharpe R, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010;70(5):2085–2094.
   PubMed Web of Science ®Google Scholar
• Formisano L, Lu Y, Servetto A, et al. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nat Commun. 2019;10(1):1373.
   PubMedGoogle Scholar
• Burstein HJ, Cirrincione CT, Barry WT, et al. Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). J Clin Oncol. 2014;32(35):3959–3966.
   PubMed Web of Science ®Google Scholar
• Sudhan DR, Schwarz LJ, Guerrero-Zotano A, et al. Extended adjuvant therapy with neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ER(+)/HER2(+) breast cancers: implications to the ExteNET trial. Clin Cancer Res off J Am Assoc Cancer Res. 2019 Jan 15;25(2):771–783.
   PubMed Web of Science ®Google Scholar
• Toy W, Weir H, Razavi P, et al. Activating ESR1 mutations differentially affect the efficacy of ER antagonists. Cancer Discov. 2017;7(3):277–287.
   PubMed Web of Science ®Google Scholar
• Weir HM, Bradbury RH, Lawson M, et al. AZD9496: an oral estrogen receptor inhibitor that blocks the growth of ER-positive and ESR1-mutant breast tumors in preclinical models. Cancer Res. 2016;76(11):3307–3318.
   PubMed Web of Science ®Google Scholar
• Bihani T, Patel HK, Arlt H, et al. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), has antitumor activity in multiple ER(+) breast cancer patient-derived xenograft models. Clin Cancer Res off J Am Assoc Cancer Res. 2017 Aug 15;23(16):4793–4804.
   PubMed Web of Science ®Google Scholar
• Guo S, Zhang C, Bratton M, et al. ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models. Oncotarget. 2018;9(6):6924–6937.
   PubMedGoogle Scholar
• De Savi C, Bradbury RH, Rabow AA, et al. Optimization of a novel binding motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist. J Med Chem. 2015 Oct 22;58(20):8128–8140.
   PubMed Web of Science ®Google Scholar
• Nardone A, Weir H, Delpuech O, et al. The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. Br J Cancer. 2019 Feb 01;120(3):331–339.
   PubMed Web of Science ®Google Scholar
• Hamilton EP, Patel MR, Armstrong AC, et al. A first-in-human study of the new oral selective estrogen receptor degrader AZD9496 for ER+/HER2− advanced breast cancer. Clin Cancer Res. 2018;24(15):3510–3518.
   PubMed Web of Science ®Google Scholar
• Bihani T, Patel HK, Arlt H, et al. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), has antitumor activity in multiple ER+ breast cancer patient-derived xenograft models. Clin Cancer Res. 2017;23(16):4793.
   PubMed Web of Science ®Google Scholar
• Garner F, Shomali M, Paquin D, et al. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 2015;26(9):948–956.
   PubMed Web of Science ®Google Scholar
• Liu J, Zheng S, Akerstrom VL, et al. Fulvestrant-3 boronic acid (ZB716): an orally bioavailable Selective Estrogen Receptor Downregulator (SERD). J Med Chem. 2016 Sep 08;59(17):8134–8140.
   PubMed Web of Science ®Google Scholar